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Sex-specific Long-term Blood Pressure Regulation:
Modeling and Analysis
Jessica Leete1, Anita Layton2,3
Abstract
Hypertension is a global health challenge: it affects one billion people worldwide
and is estimated to account for > 60% of all cases or types of cardiovascular
disease. In part because sex differences in blood pressure regulation mecha-
nisms are not sufficiently well understood, fewer hypertensive women achieve
blood pressure control compared to men, even though compliance and treat-
ment rates are generally higher in women. Thus, the objective of this study
is to identify which factors contribute to the sexual dimorphism in response to
anti-hypertensive therapies targeting the renin angiotensin system (RAS). To
accomplish that goal, we develop sex-specific blood pressure regulation models.
Sex differences in the RAS, baseline adosterone level, and the reactivity of re-
nal sympathetic nervous activity (RSNA) are represented. A novel aspect of
the model is the representation of sex-specific vasodilatory effect of the bound
angiotensin II type two receptor (AT2R-bound Ang II) on renal vascular resis-
tance. Model simulations suggest that sex differences in RSNA are the largest
cause of female resistance to developing hypertension due to the direct influence
of RSNA on afferent arteriole resistance. Furthermore, the model predicts that
the sex-specific vasodilatory effects of AT2R-bound Ang II on renal vascular
resistance may explain the higher effectiveness of angiotensin receptor block-
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ers in treating hypertensive women (but not men), compared to angiotensin
converting enzyme inhibitors.
Keywords: renin angiotensin system, ACE inhibitors, angiotensin receptor
blockers, hypertension, blood pressure
Introduction
Hypertension is a global health challenge: it affects one billion people and is
estimated to account for > 60% of all cases or types of cardiovascular disease.
Interestingly, women have lower blood pressure than men before menopause but
higher afterwards [1, 2]. Yet, hypertensive men and women are typically treated
using the same approach. In part due to our insufficient knowledge regarding
sex-specific blood pressure regulation mechanisms, fewer women achieve blood
pressure control compared to men, even though compliance and treatment rates
are higher in women [3]. These data highlight the critical need to better under-
stand the mechanisms of blood pressure control in both sexes and cast doubt
on the current “one size fits all” therapeutic approach.
Sex differences in blood pressure and the prevalence of hypertension have
been reported in a number of mammalian and avian species [4]. In humans [5]
and in genetic models of hypertension such as spontaneously hypertensive rats
(SHR) and Dahl salt-sensitive rats [6], males develop earlier and more severe
hypertension than females. To date, the mechanisms underlying male-female
differences in blood pressure control remain incompletely understood.
Hypertension is undoubtedly a multifactorial disease with contributions from
and affecting multiple organs [7, 8, 9, 10, 11, 12]. In particular, the kidney is
a key (albeit not sole) determinant of blood pressure and of sex differences in
hypertension [13]. That role is evident in transplantation studies, where blood
pressure “goes with” the kidney: transplanting a kidney from a hypertensive
rat into a normotensive rat induces hypertension in the recipient [14]. Essential
for the kidneys long-term control of blood pressure is the pressure-natriuresis














Table 1: List of Acronyms
Acronym Definition
ACE angiotensin converting enzyme




Ang I angiotensin I
Ang II angiotensin II
Ang (1-7) angiotensin (1-7)
Ang IV angiotensin IV
ANP atrial naturetic peptide
ARB angiotensin receptor blocker
AT1R - bound Ang II angiotensin type 1 receptor bound angiotensin II
AT2R - bound Ang II angiotensin type 2 receptor bound angiotensin II
GFR glomerular filtration rate
MAP mean arterial pressure
NEP neutral endopeptidase
PRA plasma renin activity
PRC plasma renin concentration
RAS renin angiotensin system
RSNA renal sympathetic nervous activity














Na+ excretion, which in turn lowers salt and water retention and reduces ef-
fective circulating volume. Under physiological conditions, females exhibit a
leftward shift in the pressure-natriuresis relation relative to males, such that
females excrete the same amount of Na+ as males at a lower arterial pres-
sure [15, 16]. Pressure-natriuresis responses encompass multiple levels of Na+
transporter regulation [17, 18], and are substantially modulated by the renin-
angiotensin system (RAS) [19]. The RAS is a non-sex hormonal system critical
for maintaining blood pressure and effective circulating volume. For instance,
one of the peptides angiotensin (Ang) II, through the angiotensin II type 1 re-
ceptor (AT1R), induces vasoconstriction and, via its effects on kidney function,
enhance Na+ and fluid retention. These vascular and tubular actions serve to
maintain or raise blood pressure. However, Ang II can also bind to the an-
giotensin II type 2 receptor (AT2R) which induces vasodilation.
In the past few years, an explosion of data has emerged concerning sex
differences in the RAS [20, 21, 22, 23], in kidney function [15, 24, 25], and
in responses to anti-hypertensive therapies targeting the RAS. For instance,
the benefits of chronic treatment of angiotensin converting enzyme inhibitors
(ACEI) in women have been reported to lessen over time [26], while angiotensin
receptor blockers (ARB) reduce blood pressure more in women than in men
[27]. That observed stronger advantage of ARB over ACEI in women relative to
men may be attributed to the sex differences in intrarenal RAS components. To
identify the physiological mechanisms underlying those differences, we develop
sex-specific computational models of blood pressure control that include the
kidney and the RAS. Our model is based on major components of the seminal
computational model for long-term blood pressure regulation by Guyton et al.
[28]; that model has since been revised and extended by a number of researchers
[29, 30, 31, 32, 33]. However, none of these models are gender specific. Thus,
the present sex-specific models are the first to capture the key sex differences
in blood pressure regulation mechanisms. This distinguishing feature allows
our models to identify the physiological mechanisms that lead to the sexual














and women’s responses to ACEI and ARB.
Materials and methods
Blood pressure regulation model
The present models are an expansion of the long-term blood pressure reg-
ulation models by Hallow et al. [30] and by Karaaslan et al. [29], which are
in terms based on the model by Guyton et al. [28]. These models describe,
using a large system of coupled nonlinear algebraic differential equations, the
interactions among the cardiovascular system, the renal system, the renal sym-
pathetic nervous system, the endocrine (renin-angiotensin) system, and how
these systems regulate blood pressure and respond to various perturbations.
For instance, renal blood flow is adjusted, via renal autoregulatory mechanisms
[34, 35], according to hormonal and nervous inputs; and renal blood flow deter-
mines, in part, Na+ excretion, which impacts blood pressure. We incorporate
the RAS as done in [30] while keeping the single nephron model as done in [29].
A major goal of this study is to identify the mechanisms that underlie the
stronger cardiovascular benefits of ARB over ACEI in women compared to men.
To that end, we incorporate into the published blood pressure regulation models
[30, 29] a detailed, sex-specific representation of the RAS, the target of ACEI and
ARB. The RAS model is adopted from a rat RAS model previously published
by us [36], with parameters refit separately for men and women (see below).
Sex-specific model parameters are identified to represent the well-known sex
differences in the RAS and in renal sympathetic nervous activity (RSNA; see
below). A schematic diagram of the blood pressure regulation model is shown
in Fig. 1. Model equations and parameters not described in detail here can be
found in Ref. [29].
Renin-angiotensin system model
The present models are the first long-term blood pressure regulation models
























































































Figure 1: Schematic model of blood pressure regulation. Red nodes denote variables that
describe cardiovascular function; green nodes, renal hemodynamics; orange nodes, renal Na+
handling and urine production; blue nodes, the RAS. ADH, anti-diuretic hormone; MAP, mean
arterial pressure; ANP, atrial natruietic peptide; RSNA, renal sympathetic nervous activity;
PRC, plasma renin concentration; PRA, plasma renin activity; AGT, angiotensinogen; Ang
I, angiotensin I; Ang II, angiotensin II; AT1R-bound Ang II, angiotensin II type 1 receptor
bound angiotensin II; AT2R-bound Ang II, angiotensin II type 2 receptor bound angiotensin
II; ALD, aldosterone.
angiotensinogen (AGT) to Ang (1-7)/Ang II/Ang IV. A schematic diagram that
depicts that reaction cascade is shown in Fig. 2. Below we describe the RAS
model equations.
AGT is catalytically cleaved by plasma renin activity (PRA) to produce
Ang I. The rate of change of [AGT] is given by the production rate kAGT, its
conversion to Ang I, and the decay based on its half life hAGT.
d[AGT]
dt




Renin is secreted at the rate Rsec. It has a baseline rate of Nrs and is
dependent on the feedback from [AT1R-bound Ang II](νAT1), where A and B































Figure 2: Schematic model of the renin-angiotensin system. Corresponds to the blue nodes






Rsec = Nrs × νAT1
The plasma renin concentration (PRC) is dependent on Rsec and decays with
a half life of hrenin. PRA is related to [PRC] by a fixed constant of XPRC−PRA
which was determined by [30] from the ratio of PRA to PRC in normotensive







PRA = [PRC] ×XPRC−PRA (3)
Ang I is converted into other forms through angiotensin converting enzyme
(ACE), chymase, and neutral endopeptidase (NEP) activity; the respective re-
action rate constants are denoted cACE, cchym, and cNEP. The half life of Ang I
is denoted hAng I.
d[Ang I]
dt

















Ang II is converted from Ang I through ACE and chymase and then con-
verted into Ang (1-7) through ACE2 at the rate cACE2. Ang II also binds to
the AT1R and AT2R at rates cAT1R and cAT2R, respectively. We assume that
Ang II, AT1R-bound Ang II, and AT2R-bound Ang II have half lives hAng II,
hAT1R, and hAT2R, respectively.
d[Ang II]
dt
= (cACE + cchym)[Ang I] − (cACE2 + cAng II=Ang IV + cAT1R + cAT2R)





= cAT1R[Ang II] −
ln(2)
hAT1R
[AT1R-bound Ang II] (6)
d[AT2R-bound Ang II]
dt
= cAT2R[Ang II] −
ln(2)
hAT2R
[AT2R-bound Ang II] (7)
Ang (1-7) is converted by NEP from Ang I and by ACE2 from Ang II, and
it decays with a half life of hAng (1-7).
d[Ang (1-7)]
dt




Ang IV is converted from Ang II at the rate cAng II=Ang IV and decays with
a half life of hAng IV.
d[Ang IV]
dt




Effects of RAS on blood pressure
The RAS regulates blood pressure and fluid balance primarily via its effects
on the kidney. Specifically,
• ALD enhances Na+ reabsorption along the distal tubule and the collecting
duct;
• AT1R-bound Ang II enhances Na+ reabsorption along the proximal tubule,
and increases afferent and efferent arteriole resistance.
A less well-studied aspect is the blood pressure-lowering effects of AT2R-














effect of AT1R-bound Ang II) [37]. In general, males have a higher AT1R:AT2R
ratio than females [37, 38]. In fact, in the kidney of the adult male rat, AT2R
have been reported to be absent or only present at low levels [39]. Given these
observations, it has been proposed that AT2R-bound Ang II may play a sig-
nificant role in the sex differences in blood pressure regulation and in patients’
responses to ACEI and ARB.
To test the validity of this hypothesis, we incorporate the vasodilatory effect
of AT2R-bound Ang II into only the female blood pressure regulation model.
The equations below present the interaction between AT2R-bound Ang II and
renal vascular resistance. We adopt the following notations. Afferent arteriole
resistance (Raa) is the baseline resistance (Raa−ss = 31.67 mmHg min l
−1)
multiplied by the effects of RSNA (βRSNA), tubuloglomerular feedback (ΣTGF ),
the myogenic effect (Σmyo), AT1R-bound Ang II (ΨAT1R−AA) and AT2R-bound
Ang II (ΨAT1R−AA). Efferent arteriole resistance (Rea) is the baseline resistance
(Rea−ss = 51.66 mmHg min l
−1) multiplied by the effects of AT1R-bound Ang
II (ΨAT1R−EA) [30] and AT2R-bound Ang II (ΨAT2R−EA). βRSNA and ΣTGF
are given by Karaaslan et al. [29] while ΨAT1R−AA and ΨAT1R−EA are given
by Hallow et al. [30].
Raa = Raa−ss × βRSNA × ΣTGF × Σmyo × ΨAT1R−AA × ΨAT2R−AA (10)
Rea = Rea−ss × ΨAT1R−EA × ΨAT2R−EA (11)
We assume that ΨAT2R−AA and ΨAT2R−EA are linearly decreasing functions
of [AT2R-bound Ang II], where [AT2R-bound Ang II]eq denotes the equilibrium
















0.025([AT2R − bound Ang II]eq





0.021([AT2R − bound Ang II]eq
−[AT2R − bound Ang II]) + 1 in females
1 in males
(13)
Together, the effects on arteriolar resistance ΨAT2R−AA and ΨAT2R−EA will
impact glomerular filtration rate (GFR), which in turn determines fluid and
Na+ excretion, and eventually blood pressure and fluid balance.
Afferent and efferent arteriole resistance together control the renal blood
flow (φrb)
Rr = Raa +Rea (14)
φrb = MAP/Rr (15)
The glomurlar filtration rate (φGFR) is the product of the net filtration
pressure (Pf ) and a constant glomerular capillary filtration coefficient (Cgcf ).
The net filtration pressure (Pf ) is in turn given by the difference between the
glomerular hydrostatic pressure (Pgh) and the sum of the Bowman hydrostatic
pressure (PB) and the glomerular osmotic pressure (Pgo). PB and Pgo are
assumed known a priori. The glomerular hydrostatic pressure (Pgh) is calculated
from the difference between MAP and the mean afferent arteriolar pressure,
which is given by the product of φrb and Raa.
φGFR = Pf × Cgcf (16)
Pf = Pgh − (PB + Pgo) (17)















Besides the effects of AT2R-bound Ang II, the models also represent sex
differences in the RAS, baseline aldosterone (ALD) levels, and RSNA sensitivity.
The RAS. To identify sex-specific RAS model parameters, we apply RAS
hormone peptide levels from the literature (see Table 2 and description below)
and solve for sex-specific RAS reaction rate constants as done in [36]. These
RAS reaction rates, shown in Table 3, are used in the hypertensive simulations.
Table 2: Human RAS hormone levels.
Normotensive
Hormone Unit Male Female
[AGT] fmol/ml 483900[40] 512770 [41]
[Ang I] fmol/ml 7.5[42] 7.5[43, 44]
[Ang II] fmol/ml 4.75[42] 4.75[44]
[Ang (1-7)] fmol/ml 14[45] 9.33 [46]
[Ang IV] fmol/ml
[AT1R - bound Ang II] fmol/ml
[AT2R - bound Ang II] fmol/ml 5.4[47] 5.4[38]
Baseline ALD. Males have higher levels of ALD than females [48]. For the
male model, we keep the baseline level of 85 ng/l from [29]. For the female model,
we use the ratio of male to female ALD reported in Ref. [48] to determine the
female baseline ALD level to be 69.2 ng/l.
RSNA. Females have less excitable and more easily repressed RSNA [49].
RSNA is affected by mean arterial pressure (MAP) and right atrial pressure
(Pra). Mathematically, RSNA is the baseline level (Nrsna = 1) multiplied by the
effects of MAP (αmap) and the effects of Pra (αrap) as shown in Eqs. 19 and 20














Table 3: Reaction rate constants solved for in the linear system for male and female nor-
motensive humans.
Reaction Rate Constant Unit Male Female
[PRC] fmol/ml/min 17.72 17.72
PRA fmol/ml/min 18.02 18.02
kAGT fmol/ml/min 577.04 610.39
cACE 1/min 0.88 1.41
cchym 1/min 0.09 0.15
cNEP 1/min 0.04 0.06
cACE2 1/min 0.0078 0.004
cAngII=AngIV 1/min 0.25 0.04
cAT1 1/min 0.17 0.03
cAT2 1/min 0.07 0.04
[AT1R − boundAngII] fmol/ml 13.99 3.78
[AngIV] fmol/ml 0.86 1.36
we introduce a new step in the female model, Eq. 22.




αrap = 1 − 0.008(mmHg)−1Pra (20)








Note that the baseline value of rsna0 is 1. Thus, the female rsna formula
implies lower RSNA levels at higher levels of stimulation (i.e., slower increase















Responses to angiotensin infusion
Angiotensin infusion experiments are commonly done in both animals and
humans to characterize the body’s reaction. We simulate the Ang I and II
infusion experiments in [50] by adding to Eqs. 4 and 5 infusion constants kI =
0.44833 fmol/ml/min and kII = 0.3633 fmol/ml/min, respectively to simulate
the constant infusion rate of Ang I and II used in the study.
The key difference between the model’s responses to Ang I and Ang II in-
fusion is the direction of change in [Ang I] (Fig. 3a). Ang I infusion, naturally,
increases [Ang I], but Ang II infusion decreases [Ang I]. The opposite responses
can be explained as follows. Both Ang I and Ang II infusion raises [AT1R-bound
Ang II]. By means of a feedback mechanism (depicted in Fig. 2), the higher
[AT1R-bound Ang II] suppresses PRA. Taken in isolation, the lower PRA would
decrease [Ang I] and [Ang II]. Indeed, this is what was observed with the Ang
II infusion simulation. For the Ang I infusion simulation, however, the added
Ang I overwhelms competing factors, resulting in an increase in [Ang I].
The predicted response to Ang II infusion shows a greater sexual dimorphism
than Ang I infusion. This can be attributed to the significantly larger male-to-
female difference between reaction rate constants in the Ang II reaction (Eq. 5)
compared to Ang I (Eq. 4); see Table 3. As a result, a given stimulus generally
yields smaller changes in [AT1R-bound Ang II] and [AT2R-bound Ang II] in
females than in males (Figs. 3c and 3d). With both Ang I and Ang II infusion,
the lower [AT1R-bound Ang II] in females cause smaller increases in MAP by
elevating afferent arteriole resistance, Na+ reabsorption in the proximal tubule,
and Na+ reabsorption in the distal tubule (through effects on ALD levels) by
less than in the male model.
Responses to various hypertensive stimuli
Hypertension is a multifactorial disease, with causes including arterial stiff-














(a) [Ang I] (b) [Ang II]
(c) [AT1R-bound Ang II] (d) [AT2R-bound Ang II]
(e) Afferent Arteriole Resistance (f) MAP
Figure 3: Predicted percent change from control due to Ang I and Ang II infusion.
nervous system. To assess the sensitivity of blood pressure to key contributors
of hypertension, we induce hypertension, in both the male and female models,
by individually increasing the following model parameters: systemic vascular
resistance, afferent arteriole resistance, proximal tubule Na+ reabsorption, dis-
tal tubule Na+ reabsorption, collecting duct Na+ reabsorption, renin secretion,
ALD secretion, and RSNA (Fig. 4). The amount of increase for each parameter
is selected to represent a large increase within physiological bounds.
Both the male and female models predict that increases in afferent arteriole
resistance induce the largest increase in extracellular fluid volume and thus














effects, in part, because of the activation of the autoregulatory response, which
elevates renal blood flow, GFR, and eventually urine and Na+ excretion, via
the dilation of the afferent arteriole. That compensatory response is nullified in
the case where afferent arteriole resistance is assumed a priori to be elevated.
Indeed, increased afferent arteriole resistance lowers renal blood flow and GFR,
whereas all other cases predict an opposite change in these variables. It is
noteworthy that increased afferent arteriole resistance leads to similar increases
in Na+ amount as other causes of hypertension. Instead, the increase in MAP
stems from water retention as extracellular fluid volume increases by double
that of the next largest cause of hypertension, RSNA (Fig. 4b).
Explaining sex differences in response to hypertensive stimulus
In the next set of simulations, we seek to explain men’s higher suscepti-
bility to hypertension, compared to women, in response to increased afferent
arteriole resistance. In our models, afferent arteriole resistance is controlled
through multiple feedback systems, including RSNA, AT1R-bound Ang II, and
AT2R-bound Ang II — all of which exhibit sex differences. When baseline af-
ferent arteriole resistance is elevated, each feedback system reacts to keep the
effective afferent arteriole resistance near normotensive levels. Consequently,
male afferent arteriole resistance increases from 32.2 mmHg to 52.4 mmHg (a
62.6% increase) while female afferent arteriole resistance only increases from
32.1 mmHg to 48.2 mmHg (a 50.2% increase). Thus, despite the same increase
in the baseline afferent arteriole resistance parameter, the female model ex-
hibits a significantly smaller increase in afferent arteriole resistance. This sex
difference can be attributed primarily to the stronger RSNA-mediated feedback
mechanisms in females: RSNA stimulation of afferent arteriole resistance drops
by 51.2% percent in the female model, but only by 47.8% in the male model.
Compared to RSNA, the two other (RAS-mediated) feedback systems show a
much smaller male-female difference in response to changes in baseline afferent
arteriole resistance. Thus we hypothesize that RSNA is the main cause of female














(a) Change in MAP.
(b) Change in Extracellular Fluid Volume. (c) Change in Total Na+ Amount.
Figure 4: Change in selected variables from various causes of hypertension. The chosen














Figure 5: Predicted blood pressure in baseline male and female (two blues) and three instances
of male model with one trait set to female value (green and two yellows). Blood pressure was
obtained for control conditions (lower) and hypertensive conditions induced by elevation in
afferent arteriole resistance (upper).
To test this hypothesis, we conduct model simulations using the male model
with one trait set to the corresponding female value at a time (Fig. 5). Specifi-
cally, we induce hypertension in three variants of the male model by increasing
afferent arteriole resistance by 250%. The three variants are: one with base-
line ALD level replaced by the female value (e.g., 69.2 ng/l instead of 85 ng/l),
one with female RAS parameters, and another with the female effects of RSNA
(Eq. 22). Each of these traits were described previously. The variant of the
male model that yields blood pressure most similar to the female model will
have the female trait that may best explain the sex difference in response to
increased afferent arteriole resistance. Results are shown in Fig. 5.
The male models with female ALD level or RAS parameters behave simi-
larly to the baseline male model, in the sense that the higher afferent arteriole
resistance yields similar increases in MAP. In contrast, the male model with
female RSNA acts similarly to the female model. Thus, we conclude that in our
models, female protection against increased afferent arteriole resistance is due,















In the next set of simulations, we investigate the sex-specific responses to
two classes of hypertensive therapies that target the RAS. We focus on renal
hypertension, which is caused by the narrowing of the afferent arterioles, mod-
eled by a higher baseline afferent arteriole resistance. We consider two types
of anti-hypertensive drugs. The first, ACEI, block ACE from converting Ang I
into Ang II. To simulate their effects, we reduce cACE by a target level γACE:
cACE = c
0
ACE ∗ (1 − γACE) (23)
where 0 ≤ γACE ≤ 1. To determine the value of γACE, we compare our model to
experimental data. Nussberger et al. found that with ACEI administration, Ang
II levels in normotensive men dropped by 63% [42]. To achieve this reduction
in [Ang II] in our normotensive male model requires a γACE = 0.78. This γACE
is used in all simulations.
The second class of hypertensive drugs considered are ARB, which stop Ang




AT1R ∗ (1 − γARB) (24)
where 0 ≤ γARB ≤ 1. To determine the level of ARB, we again compare with
experimental results. Tsutamoto et al. found that with ARB, Ang II rose by
90% in humans with mild to moderate congestive heart failure [51]. As their
patients had normal blood pressure, we compare this to the normotensive male
model, which requires γARB = 0.67 to reproduce the experimental rise in Ang
II. This γARB is used in all simulations.
The effects of ACEI and ARB on MAP in men and women are summarized
in Fig. 6. These results indicate that ACEI and ARB induce a similar reduction
in MAP in men, whereas ARB yield a significantly larger MAP decrease in
women than ACEI (Fig 6).
We hypothesize that the above difference may be attributable to the dilatory














in the female model (Eqs. 12,13). When this effect is eliminated, then the sex
difference in MAP response is much attenuated. (Fig. 6). These results suggest
that the vasodilatory effects of AT2R-bound Ang II are essential for explaining
the significantly stronger MAP-lowering effect of ARB over ACEI seen in women
but not in men.
Figure 6: Change in MAP following ACEI (blue) and ARB (yellow) administration on hy-
pertensive male model (first group) and on hypertensive female models with and without the
vasodilatory effect of [AT2R-bound Ang II] (second and third groups, respectively).
Discussion
Despite known sex differences in responses to some anti-hypertensive thera-
pies, male and female hypertensive patients are typically treated with the same
therapeutic approach. The objective of this study is to apply sex-specific com-
putational models of blood pressure regulation to reveal the contribution of dif-
ferent pathways and systems to the sexual dimorphism in the pathophysiology of
hypertension and in the efficacy of commonly prescribed anti-hypertensive ther-
apies, ACEI and ARB. Our models represent physiological systems responsible
for long term blood pressure regulation, including the cardiovascular system and
the kidney [28], as well as the RAS [30] and RSNA [29]. Major novel aspects of














RAS (Table 3), ALD concentration, and the effects of AT2R-bound Ang II on
renal vascular resistance (Eqs. 12 and 13).
Model simulations indicate a stronger response, measured by increases in
MAP, in men compared to women to a number of hypertensive stimuli, includ-
ing Ang II infusion (Fig. 3f) and increased afferent arteriole resistance (Figure
4a). This difference in responses can be attributed to the sex difference in the
reaction rate constants of the RAS, to female-specific vasodilatory benefits of
AT2R-bound Ang II, and to the RSNA, which is more excitable in the male
(Figure 5).
Men’s stronger responses to ACEI and ABR relative to women. The same fac-
tors that heighten men’s sensitivity to hypertensive stimuli also enhance their
response to anti-hypertensive treatments that target the RAS. For instance,
ACEI are predicted to yield a significantly larger decrease in MAP in men (4.88
mmHg) compared to women (2.54 mmHg, Fig. 6). This result is consistent
with a study by Falconnet et al., who found that chronic ACEI decreased both
systolic and diastolic blood pressure in hypertensive men more than women
(18.9/13.3 mmHg decrease for men, vs 11.5/7.8 mmHg decrease for women)
[26]. One discrepancy between the simulation and clinical studies is that the
model predicts in both sexes significantly smaller absolute MAP reductions than
those reported in Ref. [26]. That discrepancy could be due to the effects of ACEI
beyond the RAS, such as its inhibition of the degradation of bradykinin, an in-
flammatory mediator [52]. The build up of bradykinin causes blood vessels to
dilate, thereby reducing blood pressure. Bradykinin may also contribute to the
enhanced effectiveness of ACEI in men; bradykinin signaling causes nitric oxide
release, which reduces oxidative stress [52, 53, 54, 55]. While it is ambiguous
if men or women have greater levels of oxidative stress, it has been shown that
increasing oxidative stress in male SHR increases blood pressure and vice versa,
whereas the same is not true in female SHR [56]. While important, these effects
are beyond the scope of the model.














due to ARB in the female model (4.67 mmHg) as compared to the male model
(5.50 mmHg, Fig. 6). This small difference is consistent with the findings that
hydrochlorothiazide and ARB treatment together resulted in only a 3 mmHg
greater average decrease in the female population than in the male population
[57]. In contrast, in a study of ARB treatment in patients with essential hy-
pertension, after 6 weeks of treatment ARB was found to be more effective in
women (23 mmHg decrease in systolic pressure) compared to men (15 mmHg)
[27]. The above differing, and sometimes contrasting, observations and model
predictions are a consequence of the multiple origins of hypertension.
ARB are more effective than ACEI in women, but that difference vanishes in
men. Our models predict that ARB reduce blood pressure more than ACEI
in females (4.67 versus 2.54 mmHg drop, respectively, Figure 6). This result is
consistent with the findings of a study of chronic heart failure patients treated
with either ACEI or ARB, which indicate that ARB reduced patient morbidity
more than ACEI in females [58]. No difference in patient morbidity was found
in males. It is noteworthy that our model only produces this result when the
vasodilatory effects of AT2R-bound Ang II are included in the female model;
more below.
In contrast, our model predicts no significant difference in MAP reductions
in the male model following ACEI or ARB treatment (Figure 6). Direct com-
parison of our model’s prediction with clinical or experimental data is difficult,
inasmuch as most studies failed to divide blood pressure measurements by sex.
A number of studies have shown ARBs and ACEIs to induce similar reduc-
tions in blood pressure [59, 60, 61, 62]. In contrast, Mogensen et al. found
ARB reduced systolic blood pressure more than ACEI [63] whereas Azizi et al.
and Morgan et al. reported the opposite findings [64, 65]. However, as previ-
ously noted, none of these studies divided the results by sex. Most studies had
a much larger participation from men than women (approximately two thirds
male) [59, 61, 62, 63, 64] or were almost completely male [65].














to a larger blood pressure reduction than ACEI in females, but that benefit is
not seen in men. Both ACEI and ARB lower MAP by reducing [AT1R-bound
Ang II]. In the present model, the only difference between ACEI and ARB is the
direction of change of [AT2R-bound Ang II]: ACEI cause a decrease in [AT2R-
bound Ang II], while ARB cause an increase. This opposite effect is the reason
why the introduction of the vasodilatory effects of AT2R-bound Ang II into
the model is necessary to replicating the differences in reaction to ACEI and
ARB in women. Given the observation that AT2R have been reported to be
absent or nearly so in the kidney of the adult rat [39], we incorporate the model
assumption that AT2R-bound Ang II causes the afferent and efferent arterioles
to dilate in the female kidney (Eqs. 12 and 13). The novel representation of
AT2R-bound Ang II effects leads to a cardiovascular benefit that is specific to
ARB and females: while both ACEI and ARB lowers MAP by reducing [AT1R-
bound Ang II], in females ARB, but not ACEI, also lowers MAP by reducing
arteriolar resistance (via elevating [AT2R-bound Ang II]). The MAP-lowering
effect from the reduction in afferent arteriole resistance is then compounded by
the RSNA response in female which is more easily repressed compared to men.
The potential importance of sexual dimorphism in the regulation of afferent
arteriole resistance is consistent with other model predictions. In their model of
pressure-diuresis and naturesis, Beard and Mescam found that the differential
regulation of afferent and efferent arteriole resistance was sufficient to explain the
observed differences between normotensive and hypertensive Dahl salt-sensitive
rats [66].
In summary, the cardiovascular advantages of ARB over ACEI are stronger
in women than in men because of (1) the higher AT2R expression in women es-
pecially in the afferent and efferent arterioles and (2) a less excitable and more
easily repressed RSNA in women.
Model limitations and future extensions. This study presents the first sex-
specific computational models of whole-body long-term blood pressure regu-














especially those concerning renal tubular transport and autoregulation, is rela-
tively simplistic. For example, the renal autoregulatory components, such as the
tubuloglomerular feedback and the myogenic response, can be replaced by more
comprehensive models (e.g., Refs. [67, 68, 34, 35]) with sex-specific responses
incorporated [15]. Also, if one wishes to simulate and compare the actions of
different drugs (e.g., diuretics) that target the nephron directly, one may replace
the relatively simple renal transport components (orange nodes in Fig. 1) by a
more detailed epithelial transport model (e.g., Refs. [69, 70, 71, 72, 73, 74, 75]),
with known sexual dimorphism in renal transporter expression [76, 77] incorpo-
rated as done in Ref. [78]. With the inclusion of a detailed epithelial transport
model, the drug’s effect on specific transporters can be simulated, with the
influence on, e.g., Na+ transport predicted (rather than specified a priori).
Appendix: Determining sex-specific RAS parameters
To identify sex-specific RAS model parameters, we follow the general ap-
proach in Ref. [36]. The goal is to determine the reaction rates in Eqs. 1–9. To
that end, we first set the RAS hormone peptide levels to values gleaned from
literature. The values and references are found in Table 2 and further discussed
below.
Human male concentrations are taken from Ref. [47, 40, 42, 45, 79]. Female
hormone concentrations are estimated from these male values using the male-
to-female ratios reported in the references given in Table 2, column labelled
“Female”.
With the hormone concentrations specified, the 12 unknowns are (i) [PRC],
(ii) PRA, (iii) AGT production rate (kAGT) (iv) seven reaction rate constants
(ci), (v) [Ang IV], and (vi) [AT1R-bound Ang II].
The unknowns are computed by applying the steady-state formulation of the





























[AT1R-bound Ang II] − ln(2)
hAT2R
[AT2R - bound Ang II]
With 12 unknowns and 9 equations, we need 3 additional constraints. To
that end, we impose the (i) ratio of AT1R-to-AT2R receptors (i.e., the associated
reaction rate constants), (ii) ratio of NEP-to-ACE2, and (iii) ratio of ACE-to-
Chymase. Sex-specified ratios are available for AT1R-to-AT2R receptors [38],
but not the other ratios. See Table .4.
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• Sex specific computational models of long-term blood pressure regulation introduced 
• Different enzymatic activity is key to male sensitivity to angiotensin II infusion 
• Renal sympathetic nervous activity is key to female resistance to renal hypertension  
• Angiotensin type 2 receptor key to female strength of ARB over ACEI treatment 
